No. Title Date 36 GI Innovation and GI Biome Advance to the Semi-finals of the XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy 2025-05-13 35 GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy 2025-02-02 34 GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Immunotherapy-Resistant Liver Cancer, Melanoma, and Renal Cell Carcinoma 2024-08-26 33 GI Innovation Accelerates Development of Next-Generation Anti-Obesity Drug ‘GI-213,’ Overcoming Existing Limitations 2024-08-06 32 GI Innovation raises funds for the first time after its initial public offering to accelerate clinical research and enhance bargaining power 2024-07-30 31 GI Innovation reports partial responses in pancreatic adenocarcinoma, metastatic renal cell carcinoma and urothelial bladder cancer with GI-101A in combination with KEYTRUDA® (pembrolizumab) 2024-07-15 30 Immuno-Oncology GI-102 from GI Innovation designated to Orphan Drug by U.S. FDA, gaining momentum to the global market 2024-06-11 29 Next generation Immuno-oncology, GI-102 of GI Innovation, announces that its IND was approved by U.S. FDA and GI expects powerful immune activation to combine with chemotherapy 2024-05-27 28 GI Innovation applied IND of SC GI-102, a next generation immuno-oncology, in phase 1/2 to MFDS South Korea 2024-04-08 27 Myung-Ho Jang, the founder and CSO of GI Innovation, announces a share buyback, roughly 30,000 shares 2024-03-18 Title Content < 1 2 3 4 >
